GC Corp., 10% Owner at Artiva Biotherapeutics, Inc. (ARTV), bought 1,432,291 shares at $11.52 ($16.5M) on 2026-05-11, disclosed to the SEC on 2026-05-28.
GC Corp., a 10% holder, executed the largest insider purchase in Artiva Biotherapeutics' history by buying $12.5M of stock at $11.52 per share, signaling confidence despite recent volatility. This significant capital commitment comes as the stock trades near its 52-week low, potentially offering a contrarian entry point for sophisticated traders.
The stock is currently trading at $7.61, down 16.19% over the past 30 days and 47.43% below its 52-week high of $14.475, despite a massive 296.35% gain over the last year.
The trade itself is a catalyst as it represents the largest insider purchase in the company's history. Additionally, the company is scheduled to present H1 efficacy data for its rheumatoid arthritis program at the Needham Healthcare Conference on April 15, 2026.
The stock trades at a negative forward P/E of -2.70, indicating the company is currently unprofitable. Furthermore, recent analysis notes a history of CEO selling without offsetting insider buys, which may weigh on sentiment.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $11.52 | 347,222 | $4.0M | 24.2% |
| 2 | $11.52 | 1,085,069 | $12.5M | 75.8% |
| Total | $11.52 avg | 1,432,291 | $16.5M | 100% |